This article is more than 5 years old. Information may no longer be current.

RegeneRx receives Notice of Allowance for glaucoma therapy

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

RegeneRx Biopharmaceuticals Inc. announced that it has received a Notice of Allowance of a U.S. patent for the use of thymosin beta 4, certain fragments, isoforms, derivatives and analogs to treat patients with glaucoma and elevated intraocular pressure, according to a company press release.

Thymosin beta 4 is a novel therapeutic peptide for tissue and organ protection, as well as tissue and organ repair and regeneration, the release said.

The patent will expire in 2026.